The OTEZLA® international website

This site is intended for healthcare professionals outside the U.S.


OTEZLA is an oral PDE4 inhibitor that has been included in the GRAPPA PsA treatment recommendations1,2

The 6 clinical domains of treating psoriatic arthritis: peripheral arthritis, axial disease, enthesitis, dactylitis, skin, and nails

Since the publication of these guidelines in 2016, PDE4i and IL-17i agents have been approved for the treatment of PsA

GRAPPA recommendations highlight the need to determine treatment based in part on the domains involved in PsA and drug interactions that can compromise the management of comorbidities1

The Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA) is a global network of rheumatologists and dermatologists who have provided evidence-based guidance for the treatment and management of adult patients with psoriatic arthritis.1

CS, corticosteroid; CSA, cyclosporine A; IA, intraarticular; IL-12/23i, interleukin 12/23 inhibitor; PDE4i, phosphodiesterase 4 inhibitor (apremilast); phototx, phototherapy; SpA, spondyloarthritis; TNFi, tumor necrosis factor inhibitor; vit, vitamin.


  1. Coates LC, Kavanaugh A, Mease PJ, et al. Group for research and assessment of psoriasis and psoriatic arthritis 2015 treatment recommendations for psoriatic arthritis . Arthritis Rheumatol. 2016;68(5):1060-1071.
  2. OTEZLA Summary of Product Characteristics. Amgen Europe B.V. Minervum 7061, 4817 ZK Breda, The Netherlands; 2020.
You are leaving the OTEZLA® (apremilast) website
Do you wish to leave this site?
OTEZLA International Websites
OTEZLA is approved in 54 countries*
  • United States

  • Canada

  • Australia

  • Israel

  • Switzerland

  • New Zealand

  • Austria

  • Belgium

  • Bulgaria

  • Croatia

  • Republic of Cyprus

  • Czech Republic

  • Denmark

  • Estonia

  • Finland

  • France

  • Germany

  • Greece

  • Hungary

  • Ireland

  • Italy

  • Latvia

  • Lithuania

  • Luxembourg

  • Malta

  • Netherlands

  • Poland

  • Portugal

  • Romania

  • Slovakia

  • Slovenia

  • Singapore

  • Spain

  • Sweden

  • United Kingdom

  • Norway

  • Iceland

  • Liechtenstein

  • Russia

  • Japan

  • Hong Kong

  • Kuwait

  • Taiwan

  • UAE

  • South Korea

  • Thailand

  • Lebanon

  • Qatar

  • Argentina

  • Mexico

  • Brazil

  • Malaysia

  • Oman

  • Saudi Arabia

On November 21, 2019, Amgen acquired from Celgene Corporation the worldwide rights to Otezla® (apremilast).

Effective November 21, 2019, refer to the Amgen's Terms of Use relating to the access of Amgen websites, applications and digital services and Privacy Statement concerning the collection and use of your personal information.

For information collected by Celgene prior to November 21, 2019, refer to Celgene's Terms of Use and Privacy Policy.